Inventiva Pharma is Drug Discovery in France that focus on epigenetic modulation business. They cover business area such as Inventiva SA, drug, nuclear receptor, transcription factor, epigenetic modulation, its product candidate, lanifibranor, patient, non-alcoholic steatohepatitis, nash, no approve therapy, a portfolio, pre-clinical therapy program, Service delivery and clinical stage research, oncology, fibrosis, rare disease, France, its research partnership, AbbVie, BI.
-
Epigenetic Modulation
-
50 rue de Dijon
21121 Daix
France
Private
Inventiva SAdrugnuclear receptortranscription factorepigenetic modulationits product candidatelanifibranorpatientnon-alcoholic steatohepatitisnashno approve therapya portfoliopre-clinical therapy programService delivery and clinical stage researchoncologyfibrosisrare diseaseFranceits research partnershipAbbVieBI
* We use standard office opening hours in near Inventiva Pharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Inventiva Pharma is Drug Discovery business from France that founded in - ( years old in ), Inventiva Pharma business is focusing on Epigenetic Modulation.
Inventiva Pharma headquarter office and corporate office address is located in 50 rue de Dijon 21121 Daix France.
Inventiva Pharma was founded in France.
In , Inventiva Pharma is currently focus on epigenetic modulation sector.
Above is snippet of Google Trends for "epigenetic modulation" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Inventiva Pharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
